The Central Role of Cytokines in PTSD and Major Depressive Disorder: Mechanisms and Clinical Implications

Abstract

Post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) are debilitating psychiatric conditions that are frequently comorbid and linked to chronic immune dysregulation. Increasing evidence implicates cytokine-mediated inflammation in the pathophysiology of these disorders. Cytokines, key signaling molecules of the immune system, influence central nervous system (CNS) function by crossing the blood-brain barrier or signaling via neural routes, thereby affecting neuronal circuits involved in mood regulation and cognition. Elevated levels of pro-inflammatory cytokines—such as interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ)—have been observed in both peripheral and central compartments of individuals with PTSD and MDD. These molecules contribute to microglial activation, synaptic remodeling, hippocampal atrophy, and altered neurotransmission. Furthermore, chemokines such as CXCL12 and CCL2 are implicated in stress-induced neuroplasticity impairments. Moderating factors, including genetic polymorphisms (e.g, FKBP5, CRP), early-life adversity, sex differences, and exposure type, influence individual vulnerability to immune-related neuropsychiatric outcomes. This review synthesizes current molecular and clinical evidence, highlighting how cytokine dysregulation bridges peripheral inflammation and CNS pathology. It also explores emerging therapeutic strategies targeting inflammatory pathways and discusses the promise of biomarker-based approaches and machine learning for patient stratification and personalized treatment.

Keywords

Cytokine / Post-traumatic stress disorder / Major depressive disorder / Interleukin / TNF-α / FKBP5

Author Contributions

Conceptualization, X.-Z.H. & L.Z.; Formal Analysis, X.-Z.H. & L.Z.; Resources, X.-Z.H. & L.Z.; Writing—Original Draft Preparation, L.Z.; Writing—Review & Editing, X.-Z.H. & L.Z.; Visualization, X.-Z.H. & L.Z.

Ethics Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data sharing is not applicable.

Funding

This research received no external funding.

Declaration of Competing Interest

No conflict of interests has been declared.

Disclaimer Statement

The opinions and assertions expressed herein are those of the authors and do not reflect the official policy or position of the Uniformed Services University of the Health Sciences or the Department of Defense and Henry M. Jackson Foundation for the Advancement of Military Medicine.

References

[1] Gratacos J, Collado A, Filella X, Sanmarti R, Canete J, Llena J, et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br. J. Rheumatol. 1994, 33, 927-931. doi:10.1093/rheumatology/33.10.927.

[2] Bonne O, Gill JM, Luckenbaugh DA, Collins C, Owens MJ, Alesci S, et al. Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with post-traumatic stress disorder before and after treatment with paroxetine. J. Clin. Psychiatry 2011, 72, 1124-1128. doi:10.4088/JCP.09m05106blu.

[3] Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res. 1996, 711, 163-174. doi:10.1016/0006-8993(95)01415-2.

[4] Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9, 46-56. doi:10.1038/nrn2297.

[5] Dantzer R, Wollman EE, Vitkovic L, Yirmiya R.Cytokines, stress, and depression. Conclusions and perspectives. Adv Exp Med. Biol. 1999, 461, 317-329. doi:10.1007/978-0-585-37970-8_17.

[6] Von Känel R, Hepp U, Kraemer B, Traber R, Keel M, Mica L, et al. Evidence for low-grade systemic pro-inflammatory activity in patients with post-traumatic stress disorder. J. Psychiatr. Res. 2007, 41, 744-752. doi:10.1016/j.jpsychires.2006.06.009.

[7] Gill JM, Saligan L, Woods S, Page G. PTSD is associated with an excess of inflammatory immune activities. Perspect Psychiatr. Care 2009, 45, 262-277. doi:10.1111/j.1744-6163.2009.00229.x.

[8] Spivak B, Shohat B, Mester R, Avraham S, Gil-Ad I, Bleich A, et al. Elevated levels of serum interleukin-1 beta in combat-related post-traumatic stress disorder. Biol. Psychiatry 1997, 42, 345-348. doi:10.1016/s0006-3223(96)00375-7.

[9] Nkiliza A, Joshi U, Evans JE, Ait-Ghezala G, Parks M, Crawford F, et al. Adaptive Immune Responses Associated with the Central Nervous System Pathology of Gulf War Illness. Neurosci. Insights 2021, 16, 26331055211018458. doi:10.1177/26331055211018458.

[10] Passos IC, Vasconcelos-Moreno MP, Costa LG, Kunz M, Brietzke E, Quevedo J, et al. Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. Lancet Psychiatry 2015, 2, 1002-1012. doi:10.1016/S2215-0366.

[11] Lindqvist D, Wolkowitz OM, Mellon S, Yehuda R, Flory JD, Henn-Haase C, et al. Pro-inflammatory milieu in combat-related PTSD is independent of depression and early life stress. Brain Behav. Immun. 2014, 42, 81-88. doi:10.1016/j.bbi.2014.06.003.

[12] Maes M, Lin AH, Delmeire L, Van Gastel A, Kenis G, De Jongh R, et al. Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in post-traumatic stress disorder following accidental man-made traumatic events. Biol. Psychiatry 1999, 45, 833-839. doi:10.1016/s0006-3223.

[13] Pace TW, Heim CM. A short review on the psychoneuroimmunology of post-traumatic stress disorder: from risk factors to medical comorbidities. Brain Behav. Immun. 2011, 25, 6-13. doi:10.1016/j.bbi.2010.10.003.

[14] Deslauriers J, Powell S, Risbrough VB. Immune signaling mechanisms of PTSD risk and symptom development: insights from animal models. Curr. Opin. Behav. Sci. 2017, 14, 123-132. doi:10.1016/j.cobeha.2017.01.005.

[15] Michopoulos V, Powers A, Gillespie CF, Ressler KJ, Jovanovic T. Inflammation in Fear- and Anxiety-Based Disorders: PTSD, GAD and Beyond. Neuropsychopharmacology 2017, 42, 254-270. doi:10.1038/npp.2016.146.

[16] Brenhouse HC, Danese A, Grassi-Oliveira R. Neuroimmune Impacts of Early-Life Stress on Development and Psychopathology. Curr. Top Behav. Neurosci. 2019, 43, 423-447. doi:10.1007/7854_2018_53.

[17] Haroon E, Miller AH, Sanacora G. Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders. Neuropsychopharmacology 2017, 42, 193-215. doi:10.1038/npp.2016.199.

[18] Kruse M, Steudte-Schmiedgen S, Wessa M. From inflammation to PTSD: a review of biomarkders and pathways. Curr. Opin. Psychol. 2021, 41, 72-78.

[19] Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65, 732-741. doi:10.1016/j.biopsych.2008.11.029.

[20] Zhang L, Hu XZ, Li X, Chen Z, Benedek DM, Fullerton CS, et al. Potential chemokine biomarkers associated with PTSD onset, risk and resilience as well as stress responses in US military service members. Transl. Psychiatry 2020, 10, 31. doi:10.1038/s41398-020-0693-1.

[21] Yehuda R, Flory JD, Pratchett LC, Buxbaum J, Ising M, Holsboer F. Putative biological mechanisms for the association between early life adversity and the subsequent development of PTSD. Psychopharmacology 2010, 212, 405-417. doi:10.1007/s00213-010-1969-6.

[22] Gola H, Engler H, Sommershof A, Adenauer H, Kolassa S, Schedlowski M, et al. Post-traumatic stress disorder is associated with an enhanced spontaneous production of pro-inflammatory cytokines by peripheral blood mononuclear cells. BMC Psychiatry 2013, 13, 40. doi:10.1186/1471-244X-13-40.

[23] Martinac M, Pehar D, Karlović D, Babić D, Marčinko D, Jakovljević M. Metabolic syndrome, activity of the hypothalamic-pituitary-adrenal axis and inflammatory mediators in depressive disorder. Acta Clin. Croat. 2014, 53, 55-71.

[24] Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 2001, 58, 445-452. doi:10.1001/archpsyc.58.5.445.

[25] Felger JC, Haroon E, Patel TA, Goldsmith DR, Wommack EC, Woolwine BJ, et al. What does plasma CRP tell us about peripheral and central inflammation in depression? Mol. Psychiatry 2020, 25, 1301-1311. doi:10.1038/s41380-018-0096-3.

[26] Hodes GE, Kana V, Menard C, Merad M, Russo SJ.Neuroimmune mechanisms of depression. Nat. Neurosci. 2015, 18, 1386-1393. doi:10.1038/nn.4113.

[27] Kiecolt-Glaser JK, Derry HM, Fagundes CP. Inflammation: depression fans the flames and feasts on the heat. Am J Psychiatry 2015, 172, 1075-1091. doi:10.1176/appi.ajp.2015.15020152.

[28] Rosenblat JD, Cha DS, Mansur RB, McIntyre RS. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 53, 23-34. doi:10.1016/j.pnpbp.2014.01.013.

[29] Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70, 31-41. doi:10.1001/2013.jamapsychiatry.4.

[30] Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367, 29-35. doi:10.1016/S0140-6736(05)67763-X.

[31] Gupta MA, Jarosz P, Gupta AK. Post-traumatic stress disorder (PTSD) and the dermatology patient. Clin. Dermatol. 2017, 35, 260-266. doi:10.1016/j.clindermatol.2017.01.005.

[32] Schmidt FM, Schröder T, Kirkby KC, Sander C, Suslow T, Holdt LM, et al. Pro- and anti-inflammatory cytokines, but not CRP, are inversely correlated with severity and symptoms of major depression. Psychiatry Res. 2016, 239, 85-91. doi:10.1016/j.psychres.2016.02.052.

[33] Savitz J, Drevets WC. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci. Biobehav. Rev. 2009, 33, 699-771. doi:10.1016/j.neubiorev.2009.01.004.

[34] Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 2011, 25, 181-213. doi:10.1016/j.bbi.2010.10.015.

[35] Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. Cumulative meta-analysis of interleukins 6 and 1β tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav. Immun. 2015, 49, 206-215. doi:10.1016/j.bbi.2015.06.001.

[36] Working Group I Contribution to the Fifth Assessment Report of the Intergovernmental Panel on Climate Change.In Climate Change 2013—The Physical Science Basis; Cambridge University Press: Cambridge, UK, 2014; 1-30.

[37] Colasanto M, Madigan S, Korczak D. Depression and inflamation among children and adolescents: A meta-analysis. J. Affect. Disord. 2020, 277, 940-948. doi:10.1016/j.jad.2020.09.025.

[38] Moriarity DP, van Borkulo C, Alloy L. B. Inflammatory phenotype of depression symptom structure: A network perspective. Brain Behav. Immun. 2021, 93, 35-42. doi:10.1016/j.bbi.2020.12.005.

[39] Osimo EF, Pillinger T, Rodriguez IM, Khandaker GM, Pariante CM, Howes OD. Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain Behav. Immun. 2020, 87, 901-909. doi:10.1016/j.bbi.2020.02.010.

[40] Breen MS, Tylee DS, Maihofer AX, Neylan TC, Mehta D, Binder EB, et al. PTSD Blood Transcriptome Mega-Analysis: Shared Inflammatory Pathways across Biological Sex and Modes of Trauma. Neuropsychopharmacology 2018, 43, 469-481. doi:10.1038/npp.2017.220.

[41] Krabbe KS, Reichenberg A, Yirmiya R, Smed A, Pedersen BK, Bruunsgaard H. Low-dose endotoxemia and human neuropsychological functions. Brain Behav. Immun. 2005, 19, 453-460. doi:10.1016/j.bbi.2005.04.010.

[42] Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 2016, 16, 22-34. doi:10.1038/nri.2015.5.

[43] Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013, 246, 199-229. doi:10.1016/j.neuroscience.2013.04.060.

[44] Cohen H, Zohar J, Gidron Y, Matar MA, Belkind D, Loewenthal U, et al. Blunted HPA axis response to stress influences susceptibility to post-traumatic stress response in rats. Biol. Psychiatry 2006, 59, 1208-1218. doi:10.1016/j.biopsych.2005.12.003.

[45] Sher L. Post-traumatic stress disorder and suicidal behavior. Exper. Rev. Neurother. 2020, 20, 559-568.

[46] Spivak B, Radwan M, Mester R, Ovadia H, Moisa R, Weizman A. Reduced platelet responsiveness to serotonin in post-traumatic stress disorder. Psychiatry Res. 2000, 94, 1-6.

[47] Zhang W, Xiao D, Mao Q, Xia H. Role of neuroinflammation in neurodegeneration development. Signal Trans. Target. Ther. 2023, 8, 267. doi:10.1038/s41392-023-01486-5.

[48] Barrett E, Ross RP, O'Toole PW, Fitzgerald GF, Stanton C. gamma-Aminobutyric acid production by culturable bacteria from the human intestine. J. Appl. Microbiol. 2012, 113, 411-417. doi:10.1111/j.1365-2672.2012.05344.x.

[49] Cheung SG, Goldenthal AR, Uhlemann AC, Mann JJ, Miller JM, Sublette ME. Systematic Review of Gut Microbiota and Major Depression. Front. Psychiatry 2019, 10, 34. doi:10.3389/fpsyt.2019.00034.

[50] Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 605-616. doi:10.1038/s41575-019-0173-3.

[51] Muzio L, Viotti A, Martino G. Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy. Front. Neurosci. 2021, 15, 742065. doi:10.3389/fnins.2021.742065.

[52] Woodburn SC, Bollinger JL, Wohleb ES. The semantics of microglia activation: neuroinflammation, homeostasis, and stress. J. Neuroinflamm. 2021, 18, 258. doi:10.1186/s12974-021-02309-6.

[53] Enomoto S, Kato TA. Stress Mediated Microglial Hyper-Activation and Psychiatric Diseases. Brain Nerve 2021, 73, 795-802 (). doi:10.11477/mf.1416201837.

[54] Bollinger JL, Dadosky DT, Flurer JK, Rainer IL, Woodburn SC, Wohleb ES. Microglial P2Y12 mediates chronic stress-induced synapse loss in the prefrontal cortex and associated behavioral consequences. Neuropsychopharmacology 2023, 48, 1347-1357. doi:10.1038/s41386-022-01519-7.

[55] Li B, Yang W, Ge T, Wang Y, Cui R. Stress induced microglial activation contributes to depression. Pharmacol. Res. 2022, 179, 106145. doi:10.1016/j.phrs.2022.106145.

[56] Comai S, Bertazzo A, Brughera M, Crotti S. Advances in Clinical Chemistry; Makowski GS, Ed.; Elsevier: Amsterdam, The Netherlands, 2020; Volume 95, pp. 165-218.

[57] Salminen A. Role of indoleamine 2,3-dioxygenase 1 (IDO1) and kynurenine pathway in the regulation of the aging process. Ageing Res. Rev. 2022, 75, 101573. doi:10.1016/j.arr.2022.101573.

[58] Carpenedo R, Pittaluga A, Cozzi A, Attucci S, Galli A, Raiteri M, et al. Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur. J. Neurosci. 2001, 13, 2141-2147. doi:10.1046/j.0953-816x.2001.01592.x.

[59] Dunn AJ. Techniques in the Behavioral and Neural Sciences; Steckler T, Kalin NH, Reul JMHM, Eds.; Elsevier: The Netherlands, Amsterdam, 2005; Volume 15, pp. 157-174.

[60] Mahmood Z, Davidsson A, Olsson E, Leanderson P, Lundberg AK, Jonasson L. The effect of acute exercise on interleukin-6 and hypothalamic-pituitary-adrenal axis responses in patients with coronary artery disease. Sci. Rep. 2020, 10, 21390. doi:10.1038/s41598-020-78286-2.

[61] Judd AM, Call GB, Barney M, McILMOIL CJ, Balls AG, Adams A, et al. Possible function of IL-6 and TNF as intraadrenal factors in the regulation of adrenal steroid secretion. Ann. N. Y. Acad. Sci. 2000, 917, 628-637. doi:10.1111/j.1749-6632.2000.tb05428.x.

[62] Karin O, Raz M, Tendler A, Bar A, Korem Kohanim Y, Milo T, et al. A new model for the HPA axis explains dysregulation of stress hormones on the timescale of weeks. Mol. Syst. Biol. 2020, 16, e9510. doi:10.15252/msb.20209510.

[63] Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008, 31, 464-468. doi:10.1016/j.tins.2008.06.006.

[64] Castro-Vale I, Carvalho D. The Pathways between Cortisol-Related Regulation Genes and PTSD Psychotherapy. Healthcare 2020, 8, 376. doi:10.3390/healthcare8040376.

[65] Bethin KE, Vogt SK, Muglia LJ. Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation. Proc. Natl. Acad. Sci. USA 2000, 97, 9317-9322. doi:10.1073/pnas.97.16.9317.

[66] Besedovsky HO, Del Rey A, Klusman I, Furukawa H, Arditi GM, Kabiersch A. Cytokines as modulators of the hypothalamus-pituitary-adrenal axis. J. Steroid Biochem. Mol. Biol. 1991, 40, 613-618. doi:10.1016/0960-0760(91)90284-c.

[67] Chen L, Qin Q, Huang P, Cao F, Yin M, Xie Y, et al. Chronic pain accelerates cognitive impairment by reducing hippocampal neurogenesis may via CCL2/CCR2 signaling in APP/PS1 mice. Brain Res. Bulletin 2023, 205, 110801. doi:10.1016/j.brainresbull.2023.110801.

[68] Yan Y, Su J, Zhang Z. The CXCL12/CXCR4/ACKR3 Response Axis in Chronic Neurodegenerative Disorders of the Central Nervous System: Therapeutic Target and Biomarker. Cell. Mol. Neurobiol. 2022, 42, 2147-2156. doi:10.1007/s10571-021-01115-1.

[69] Bruenig D, Mehta D, Morris CP, Harvey W, Lawford B, Young RM, et al. Genetic and serum biomarker evidence for a relationship between TNFα and PTSD in Vietnam war combat veterans. Compr. Psychiatry 2017, 74, 125-133. doi:10.1016/j.comppsych.2017.01.015.

[70] Friend SF, Nachnani R, Powell SB, Risbrough VB. C-Reactive Protein: Marker of risk for post-traumatic stress disorder and its potential for a mechanistic role in trauma response and recovery. Eur. J. Neurosc. 2022, 55, 2297-2310. doi:10.1111/ejn.15031.

[71] Kim TD, Lee S, Yoon S. Inflammation in Post-Traumatic Stress Disorder (PTSD): A Review of Potential Correlates of PTSD with a Neurological Perspective. Antioxidants 2020, 9, 107. doi:10.3390/antiox9020107.

[72] Teche SP, Rovaris DL, Aguiar BW, Hauck S, Vitola ES, Bau CH, et al. Resilience to traumatic events related to urban violence and increased IL10 serum levels. Psychiatry Res. 2017, 250, 136-140. doi:10.1016/j.psychres.2017.01.072.

[73] Paganin W, Signorini S. Inflammatory biomarkers in depression: scoping review. BJPsych. Open 2024, 10, e165. doi:10.1192/bjo.2024.787.

[74] Rocha NP, Scalzo PL, Barbosa IG, Souza MS, Morato IB, Vieira ÉL, et al. Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson’s Disease. Parkinson's Dis. 2014, 2014, 903796. doi:10.1155/2014/903796.

[75] Teixeira AL, Gama CS, Rocha NP, Teixeira MM. Revisiting the Role of Eotaxin-1/CCL11 in Psychiatric Disorders. Front. Psychiatry 2018, 9, 241. doi:10.3389/fpsyt.2018.00241.

[76] Peruzzolo TL, Pinto JV, Roza TH, Shintani AO, Anzolin AP, Gnielka V, et al. Inflammatory and oxidative stress markers in post-traumatic stress disorder: a systematic review and meta-analysis. Mol. Psychiatry 2022, 27, 3150-3163. doi:10.1038/s41380-022-01564-0.

[77] Solmi M, Sharma MS, Osimo EF, Fornaro M, Bortolato B, Croatto G, et al. Peripheral levels of C-reactive protein, tumor necrosis factor-α interleukin-6, and interleukin-1β across the mood spectrum in bipolar disorder: A meta-analysis of mean differences and variability. Brain, Behav. Immun. 2021, 97, 193-203. doi:10.1016/j.bbi.2021.07.014.

[78] Katrinli S, Oliveira NCS, Felger JC, Michopoulos V, Smith AK. The role of the immune system in posttraumatic stress disorder. Tranlational Psychiatry 2022, 12, 313.

[79] Benedetti F, Poletti S, Vai B, Mazza MG, Lorenzi C, Brioschi S, et al. Higher baseline interleukin-1β and TNF-α hamper antidepressant response in major depressive disorder. Eur. Neuropsychopharmacol 2021, 42, 35-44. doi:10.1016/j.euroneuro.2020.11.009.

[80] Fitton R, Sweetman J, Heseltine-Carp W, van der Feltz-Cornelis C. Anti-inflammatory medications for the treatment of mental disorders: A scoping review. Brain Behav. Immun. Health 2022, 26, 100518. doi:10.1016/j.bbih.2022.100518.

[81] Rizk MM, Bolton L, Cathomas F, He H, Russo SJ, Guttman-Yassky E, et al. Immune-Targeted Therapies for Depression: Current Evidence for Antidepressant Effects of Monoclonal Antibodies. J. Clin. Psychiatry 2024, 85, 23nr15243. doi:10.4088/JCP.23nr15243.

[82] Gong H, Su WJ, Deng SL, Luo J, Du ZL, Luo Y, et al. Anti-inflammatory interventions for the treatment and prevention of depression among older adults: a systematic review and meta-analysis. Transl. Psychiatry 2025, 15, 114. doi:10.1038/s41398-025-03317-3.

[83] Saban KL, Collins EG, Mathews HL, Bryant FB, Tell D, Gonzalez B, et al. Impact of a Mindfulness-Based Stress Reduction Program on Psychological Well-Being, Cortisol, and Inflammation in Women Veterans. J. General Int. Med. 2022, 37, 751-761. doi:10.1007/s11606-022-07584-4.

[84] Almeida TM, da Silva UR, Pires JP, Borges IN, Martins CR, Cordeiro Q, et al. Effectiveness of Ketamine for the Treatment of Post-Traumatic Stress Disorder - A Systematic Review and Meta-Analysis. Clin. Neuropsychiatry 2024, 21, 22-31. doi:10.36131/cnfioritieditore20240102.

[85] Wang W, Wang R, Xu J, Qin X, Jiang H, Khalid A, et al. Minocycline Attenuates Stress-Induced Behavioral Changes via Its Anti-inflammatory Effects in an Animal Model of Post-traumatic Stress Disorder. Front. Psychiatry 2018, 9, 558. doi:10.3389/fpsyt.2018.00558.

[86] Lee TD, Lee JY, Hong DY, Lee EC, Park SW, Lee MR, et al.Neuroinflammation in Post-Traumatic Stress Disorder. Biomedicines 2022, 10, 953. doi:10.3390/biomedicines10050953.

[87] Abbasi S-H, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study. J. Affect. Disord. 2012, 141, 308-314. doi:10.1016/j.jad.2012.03.033.

[88] Kohler O, Krogh J, Mors O, Benros ME. Inflammation in Depression and the Potential for Anti-Inflammatory Treatment. Curr. Neuropharmacol. 2016, 14, 732-742. doi:10.2174/1570159x14666151208113700.

[89] Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 2006, 11, 680-684. doi:10.1038/sj.mp.4001805.

[90] Du Y, Dou Y, Qang M, Wang Y, Fan H, Fan N, et al. Efficacy and acceptability of anti-infelammatory agents in major depressive disorder: a systematc review and meta-analysis. Front. Psychiatry 2024, 15. doi:10.3389/fpsyt.2024.1407529.

[91] Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress. Anxiety 2009, 26, 607-611. doi:10.1002/da.20589.

[92] Köhler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014, 71, 1381-1391. doi:10.1001/jamapsychiatry.2014.1611.

[93] Bai S, Guo W, Feng Y, Deng H, Li G, Nie H, et al. Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: A systematic review and meta-analysis of randomised controlled trials. J. Neurol. Neurosurg. Psychiatry 2020, 91, 21-32. doi:10.1136/jnnp-2019-320912.

[94] Chen B, Sun X, Huang H, Feng C, Chen W, Wu D. An integrated machine learning framework for developing and validating a diagnostic model of major depressive disorder based on interstitial cystitis-related genes. J. Affect. Disord. 2024, 359, 22-32. doi:10.1016/j.jad.2024.05.061.

[95] McQuaid RJ. Transdiagnostic biomarker approaches to mental health disorders: Consideration of symptom complexity, comorbidity and context. Brain Behav. Immun. Health 2021, 16, 100303. doi:10.1016/j.bbih.2021.100303.

[96] Papini S, Iturralde E, Lu Y, Greene JD, Barreda F, Sterling SA, et al. Development and validation of a machine learning model using electronic health records to predict trauma- and stressor-related psychiatric disorders after hospitalization with sepsis. Transl. Psychiatry 2023, 13, 400. doi:10.1038/s41398-023-02699-6.

[97] Ma H, Xu J, Li R, McIntyre RS, Teopiz KM, Cao B, et al. The Impact of Cognitive Behavioral Therapy on Peripheral Interleukin-6 Levels in Depression: A Systematic Review and Meta-Analysis. Front. Psychiatry 2022, 13, 844176. doi:10.3389/fpsyt.2022.844176.

[98] Kraus C, Kadriu B, Lanzenberger R, Zarate CA Jr, Kasper S. Prognosis and improved outcomes in major depression: a review. Transl. Psychiatry 2019, 9, 127. doi:10.1038/s41398-019-0460-3.

[99] Strawbridge R, et al. Inflammation and clinical response to treatment in depression: A meta-analysis. Eur. Neuropsychopharmacol 2015, 25, 1532-1543. doi:10.1016/j.euroneuro.2015.06.007.

[100] Dean OM, Maes M, Ashton M, Berk L, Kanchanatawan B, Sughondhabirom A, et al. Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial. Clin. Psychopharmacol. Neurosci. 2014, 12, 180-188. doi:10.9758/cpn.2014.12.3.180.

[101] Wang M, Duan F, Wu J, Min Q, Huang Q, Luo M, et al. Effect of cyclooxygenase-2 inhibition on the development of post-traumatic stress disorder in rats. Mol. Med. Rep. 2018, 17, 4925-4932. doi:10.3892/mmr.2018.8525.

[102] Knight JM, Costanzo ES, Singh S, Yin Z, Szabo A, Pawar DS, et al. The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill. Transl. Psychiatry 2021, 11, 58. doi:10.1038/s41398-020-01164-y.

[103] Howland RH. Mifepristone as a Therapeutic Agent in Psychiatry. J. Psychosoc. Nurs. Mental Health Serv. 2013, 51, 11-14. doi:10.3928/02793695-20130513-01.

[104] Kothgassner OD, Pellegrini M, Goreis A, Giordano V, Edobor J, Fischer S, et al. Hydrocortisone administration for reducing post-traumatic stress symptoms: A systematic review and meta-analysis. Psychoneuroendocrinology 2021, 126, 105168. doi:10.1016/j.psyneuen.2021.105168.

[105] Hennessy VE, Troebinger L, Iskandar G, Das RK, Kamboj SK. Accelerated forgetting of a trauma-like event in healthy men and women after a single dose of hydrocortisone. Transl. Psychiatry 2022, 12, 354. doi:10.1038/s41398-022-02126-2.

[106] Wang L, Wang R, Liu L, Qiao D, Baldwin DS, Hou R. Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis. Brain Behav. Immun. 2019, 79, 24-38. doi:10.1016/j.bbi.2019.02.021.

[107] Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011, 36, 2452-2459. doi:10.1038/npp.2011.132.

[108] Jóźwiak-Bębenista M, Sokołowska P, Wiktorowska-Owczarek A, Kowalczyk E, Sienkiewicz M. Ketamine - A New Antidepressant Drug with Anti-Inflammatory Properties. J. Pharmacol. Exp. Ther. 2024, 388, 134-144. doi:10.1124/jpet.123.001823.

[109] Alvarez-Herrera S, Escamilla R, Medina-Contreras O, Saracco R, Flores Y, Hurtado-Alvarado G, et al. Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics. Front. Endocrinol. (Lausanne) 2020, 11, 195. doi:10.3389/fendo.2020.00195.

[110] Eyre HA, Papps E, Baune BT. Treating depression and depression-like behavior with physical activity: an immune perspective. Front. Psychiatry 2013, 4, 3. doi:10.3389/fpsyt.2013.00003.

[111] Jacka FN, O’Neil A, Opie R, Itsiopoulos C, Cotton S, Mohebbi M, et al. A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial). BMC Med. 2017, 15, 23. doi:10.1186/s12916-017-0791-y.

[112] Noushad S, Ansari B, Ahmed S. Effect of nature-based physical activity on post-traumatic growth among healthcare providers with post-traumatic stress. Stress Health 2022, 38, 813-826. doi:10.1002/smi.3135.

[113] Mafla-España MA, Cauli O. Non-Pharmacological Interventions for Managing the Symptoms of Depression in Women with Breast Cancer: A Literature Review of Clinical Trials. Diseases 2025, 13, 80. doi:10.3390/diseases13030080.

[114] Dudek KA, Paton SE, Binder LB, Collignon A, Dion-Albert L, Cadoret A, et al. Astrocytic cannabinoid receptor 1 promotes resilience by dampening stress-induced blood-brain barrier alterations. Nat. Neurosci. 2025, 28, 766-782. doi:10.1038/s41593-025-01891-9.

[115] Trebaticka J, Durackova Z. Psychiatric disorders and omega-3 fatty acids. Free Radic. Biol. Med. 2014, 75 Suppl 1, S52. doi:10.1016/j.freeradbiomed.2014.10.824.

[116] Hankenson KD, Watkins BA, Schoenlein IA, Allen KG, Turek JJ. Omega-3 fatty acids enhance ligament fibroblast collagen formation in association with changes in interleukin-6 production. Proc. Soc. Exp. Biol. Med. 2000, 223, 88-95. doi:10.1046/j.1525-1373.2000.22312.x.

[117] Chiarpenello C, Brodmann K. What can the psychoneuroimmunology of yoga teach us about depression's psychopathology? Brain Behav. Immun. -Health 2024, 42, 100877. doi:10.1016/j.bbih.2024.100877.

[118] Wang X, Sundquist K, Palmér K, Hedelius A, Memon AA, Sundquist J. Macrophage Migration Inhibitory Factor and microRNA-451a in Response to Mindfulness-based Therapy or Treatment as Usual in Patients with Depression, Anxiety, or Stress and Adjustment Disorders. Int. J. Neuropsychopharmacol. 2018, 21, 513-521. doi:10.1093/ijnp/pyy001.

[119] Yao Y, Tsirka SE. The CCL2-CCR2 system affects the progression and clearance of intracerebral hemorrhage. Glia 2012, 60, 908-918. doi:10.1002/glia.22323.

[120] Shah BR, Li B, Al Sabbah H, Xu W, Mráz J. Effects of prebiotic dietary fibers and probiotics on human health: With special focus on recent advancement in their encapsulated formulations. Trends Food Sci. Technol. 2020, 102, 178-192. doi:10.1016/j.tifs.2020.06.010.

[121] Clapp M, Aurora N, Herrera L, Bhatia M, Wilen E, Wakefield S. Gut microbiota's effect on mental health: The gut-brain axis. Clin. Pract. 2017, 7, 987. doi:10.4081/cp.2017.987.

[122] Asadizeidabadi A, Hosseini S, Pyatkov A. Effects of Repetitive Transcranial Magnetic Stimulation on Tumor Necrosis Factor Alpha in Neuropsychological Disorders: A Systematic Review and Meta-Analysis. Brain Behav. 2025, 15, e70329. doi:10.1002/brb3.70329.

[123] Rajkumar RP. Immune-inflammatory markers of response to repetitive transcranial magnetic stimulation in depression: A scoping review. Asian J. Psychiatr. 2024, 91, 103852. doi:10.1016/j.ajp.2023.103852.

[124] Kavakbasi E, Van Assche E, Schwarte K, Hohoff C, Baune BT. Long-Term Immunomodulatory Impact of VNS on Peripheral Cytokine Profiles and Its Relationship with Clinical Response in Difficult-to-Treat Depression (DTD). Int. J. Mol. Sci. 2024, 25, 4196. doi:10.3390/ijms25084196.

[125] Khandaker GM, Oltean BP, Kaser M, Dibben CR, Ramana R, Jadon DR, et al. Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation. BMJ Open 2018, 8, e025333. doi:10.1136/bmjopen-2018-025333.